| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 850,739 | 811,085 | 706,785 | 708,655 |
| Cost of sales | 266,810 | 248,632 | 206,238 | 196,070 |
| Amortization of acquired intangible assets | - | - | - | 24,435 |
| Gross profit, total | 583,929 | 562,453 | 500,547 | - |
| Impairment of long-lived assets | - | - | - | 18,698 |
| Research and development | 117,290 | 108,901 | 105,310 | 100,101 |
| Sales and marketing | 250,228 | 247,118 | 264,310 | 194,653 |
| General and administrative | 241,413 | 208,582 | 220,686 | 217,201 |
| Impairment of long-lived and indefinite-lived assets | 543 | 0 | 6,251 | - |
| Total operating expenses | - | - | - | 751,158 |
| Operating expenses, total | 609,474 | 564,601 | 596,557 | - |
| Other operating income | 0 | 0 | - | 3,100 |
| Loss from operations | -25,545 | -2,148 | -96,010 | -39,403 |
| Interest expense | - | - | - | -9,607 |
| Investment income, net | 17,577 | 11,926 | 4,997 | 11,582 |
| Interest expense, net | 9,789 | 9,835 | 9,978 | - |
| Total other income | 7,788 | 2,091 | -4,981 | 1,975 |
| Net loss before tax | -17,757 | -57 | -100,991 | -37,428 |
| Income tax expense | 1,837 | 1,128 | 224 | 808 |
| Net loss | -19,594 | -1,185 | -101,215 | -38,236 |
| Increase (decrease) in net loss per share (in usd per share) | -0.1 | -0.01 | -0.54 | -0.21 |
| Net loss per sharebasic (in usd per share) | -0.1 | -0.01 | -0.54 | -0.21 |
| Weighted average common shares outstandingbasic (in shares) | 189,262,000 | 188,902,000 | 186,813,000 | 184,795,000 |
| Weighted average common shares outstandingdiluted (in shares) | 189,262,000 | 188,902,000 | 186,813,000 | 184,795,000 |
EXACT SCIENCES CORP (EXAS)
EXACT SCIENCES CORP (EXAS)